Sunesis Pharmaceuticals Inc (SNSS)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

395 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO, CA 94080

Focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. The company has built its product candidate portfolio through internal discovery and the in-licensing of novel cancer therapeutics.

Data as of 2020-11-22
Market Cap22.978 Million Shares Outstanding18.093 Million Avg 30-day Volume552.686 Thousand
P/E Ratio-0.6 Dividend Yield EPS-2.1
Price/Sales10.478 Price cash flow ratio Price free cash flow ratio-1.5
Book Value1.05 Price to Tangible Book5.3 Alpha-0.03
Short Interest Ratio % Short Interest to Float R-squared0.062964
BETA1.89869 52-week High/Low11.3 / 1.12 Stddev0.318867
View SEC Filings from SNSS instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 2 -50.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 28 42 -33.33% 10 (0.66%) 12 (0.78%) -16.67%
13F shares: 5.139 Million 3.779 Million 35.99% 3.371 Million 1.869 Million 80.37%
% Ownership 28.4031 2.3104 1129.36% 18.6297 1.1425 1530.61%
New Positions: 3 7 -57.14% 2 1 100.0%
Increased Positions 10 6 66.67% 3 1 200.0%
Closed Positions 16 13 23.08% 4 6 -33.33%
Reduced Positions 13 10 30.0% 5 2 150.0%
Total Calls 159.108 Thousand 13.592 Thousand 1070.6% 4.25 Thousand
Total Puts 31.906 Thousand 5.13 Thousand 521.95% 3.63 Thousand
PUT/CALL Ratio 0.2 0.38 -47.37% 0.85 -76.47%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SNSS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SNSS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KETCHUM STEVEN B

  • Director
0 2020-06-30 1

MISFELDT DAYTON SEE REMARKS

  • Officer
  • Director
0 2020-06-30 2

PEARCE HOMER L

  • Director
0 2020-06-30 1

STUMP DAVID C

  • Director
0 2020-06-30 1

YOUNG JAMES W

  • Director
0 2020-06-30 1

CARCHEDI STEVE

  • Director
0 2020-06-30 1

WOLFF HENRY WARD

  • Director
0 2020-06-30 1

ONETTO NICOLE

  • Director
0 2020-06-30 1

GULLOTTA TINA VP, FINANCE

  • Officer
20,500 2020-05-29 2

QUINN WILLIAM P. SEE REMARKS

  • Officer
127,697 2020-03-31 1

FOX JUDITH A. SEE REMARKS

  • Officer
0 2020-03-31 1

AISLING CAPITAL IV, LP

AISLING CAPITAL PARTNERS IV LLC

AISLING CAPITAL PARTNERS IV, LP

SCHIFF ANDREW N

ELMS STEVE

  • 10% Owner
10,100,000 2019-07-15 0

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC

MPM ONCOLOGY IMPACT MANAGEMENT LP

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

UBS ONCOLOGY IMPACT FUND L.P.

  • 10% Owner
3,331,500 2017-11-02 0

SWISHER DANIEL N JR PRESIDENT AND CEO

  • Officer
  • Director
0 2017-07-10 0

PARKER GEOFFREY M.

  • Director
0 2017-05-31 0

BJERKHOLT ERIC EVP, CFO & CORP. SECRETARY

  • Officer
0 2016-11-30 0

FUST MATTHEW

  • Director
0 2016-06-30 0

BAY CITY CAPITAL LLC

BAY CITY CAPITAL MANAGEMENT V LLC

BAY CITY CAPITAL FUND V, L.P.

BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

  • 10% Owner
5,623,815 2015-07-24 0

KIM HELEN SUSAN

  • Director
0 2015-06-30 0

CRAIG ADAM R EVP, DEVELOPMENT & CMO

  • Officer
23,452 2015-02-27 0

GROWTH EQUITY OPPORTUNITIES FUND, LLC

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

NEA PARTNERS 12, LIMITED PARTNERSHIP

NEA 12 GP, LLC

  • 10% Owner
4,659,333 2014-08-27 0

BARRETT M JAMES

  • 10% Owner
4,659,333 2014-08-27 0

KOLLURI KRISHNA KITTU

  • 10% Owner
4,659,333 2014-08-27 0

KERINS PATRICK J

  • 10% Owner
4,659,333 2014-08-27 0

DRANT RYAN D

  • 10% Owner
4,659,333 2014-08-27 0

BASKETT FOREST

  • 10% Owner
4,659,333 2014-08-27 0

BARRIS PETER J

  • 10% Owner
4,659,333 2014-08-27 0

SANDELL SCOTT D

  • 10% Owner
4,659,333 2014-08-27 0

DEPINTO JOSEPH I EVP, CCO

  • Officer
0 2014-02-28 0

HURWITZ EDWARD

  • Director
0 2013-06-28 0

GROWTH EQUITY OPPORTUNITIES FUND, LLC

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

NEA 12 GP, LLC

NEA PARTNERS 12, LIMITED PARTNERSHIP

NEWHALL CHARLES W III

KRAMLICH C RICHARD

BARRIS PETER J

PERRY MARK W

BARRETT M JAMES

SANDELL SCOTT D

  • 10% Owner
33,819,441 2010-06-30 0

ALTA BIOPHARMA PARTNERS III LP

ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

ALTA BIOPHARMA MANAGEMENT III LLC

PENHOET EDWARD

DELEAGE JEAN

CHAMPSI FARAH

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2010-06-30 0

SEMON DOMINIQUE

  • 10% Owner
3,921,095 2010-04-30 0

LINEHAN CHARLES M

  • 10% Owner
0 2009-10-30 0

TRAINOR III EUGENE A

  • 10% Owner
0 2009-10-30 0

WARBURG PINCUS EQUITY PARTNERS LP

WARBURG PINCUS & CO

WARBURG PINCUS PARTNERS LLC

WARBURG PINCUS LLC

  • 10% Owner
No longer subject to file 2009-07-17 0

EVNIN ANTHONY B

  • Director
No longer subject to file 2009-04-03 0

ALTA BIOPHARMA PARTNERS III LP

MARDUEL ALIX

PENHOET EDWARD

ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

ALTA BIOPHARMA MANAGEMENT III LLC

DELEAGE JEAN

CHAMPSI FARAH

  • 10% Owner
2,232,464 2009-04-03 0

PIERCE VALERIE L SVP & GENERAL COUNSEL

  • Officer
0 2008-06-30 0

LEFF JONATHAN S

  • Director
  • 10% Owner
0 2008-06-05 0

FODOR STEPHEN P A

  • Director
0 2008-06-05 0

WELLS JAMES A

  • Director
0 2008-06-05 0

GOLDBY STEVEN D

  • Director
0 2008-06-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SWISHER DANIEL N JR - Director - Officer PRESIDENT AND CEO

2014-03-04 15:37:08 -0500 2024-02-28 F 3,747 $6.55 d 128,017 direct 3.5714 1.4285 -26.0 17.5714 123 -33.2858 52

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments